The World Health Organization (WHO) has launched the first clinical trial of a new Ebola vaccine, dubbed Ebovax, in the Democratic Republic of Congo as part of efforts to address the ongoing outbreak in the North Kivu region. The trial is centered in the city of Beni, identified as a recent hotspot for the virus’s spread.

This vaccine study represents a critical step toward reducing the high mortality rates associated with Ebola, which has claimed thousands of lives in past epidemics. The vaccination campaign employs a ring vaccination approach, targeting healthcare workers, children aged 12 months and older, and other individuals deemed at elevated risk of infection.

Alongside Ebovax, WHO is assessing additional vaccine candidates, including Vaxzeb and others developed with messenger RNA (mRNA) technology by international research teams. These combined efforts aim to provide effective prevention tools in the absence of fully approved treatments, especially crucial in remote areas complicated by conflict and limited infrastructure.

WHO officials emphasize the necessity of close cooperation with local health authorities and community leaders to ensure both the ethical conduct of the trials and community acceptance. The organization underscores that maintaining rigorous scientific standards and transparency is vital for the success of the vaccination efforts.

The trial of Ebovax marks an important advance in global public health efforts to control Ebola and improve responses to emerging viral threats worldwide.